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ABSTRACT
Introduction Sedation is a cornerstone therapy in
the management of patients receiving mechanical
ventilation and is highly influential on outcome. Early
sedation depth appears especially influential, as early
deep sedation is associated with worse outcome when
compared with light sedation. Our research group has
shown that patients receiving mechanical ventilation in
the emergency department (ED) are exposed to deep
sedation commonly, and ED sedation depth is impactful
on intensive care unit (ICU) care and clinical outcomes.
While extensive investigation has occurred for patients in
the ICU, comparatively little data exist from the ED. Given
the influence that ED sedation seems to carry, as well
as a lack of ED-based sedation trials, there is significant
rationale to investigate ED-based sedation as a means to
improve outcome.
Methods and analysis This is a multicentre (n=3)
prospective, before-and-after pilot trial examining the
feasibility of implementing targeted sedation in the
immediate postintubation period in the ED. A cohort of
344 patients receiving mechanical ventilation in ED will
be included. Feasibility outcomes include: (1) participant
recruitment; (2) proportion of Richmond Agitation-Sedation
Scale (RASS) scores in the deep sedation range; (3)
reliability (agreement) of RASS measurements performed
by bedside ED nurses; and (4) adverse events. The
proportion of deep sedation measurements before and
after the intervention will be compared using the χ2 test.
Logistic regression will be used to compare before-and-
after differences, adjusting for potential confounders. The
inter-rater correlation coefficient will be used to assess
paired observations between a study team member and
bedside ED nurses, and to describe reliability of RASS
measurements.
Ethics and dissemination The Human Research
Protection Office at Washington University in St. Louis
School of Medicine has approved the study. The

Strengths and limitations of this study
►► This study will generate new knowledge about an

influential component of supportive care (sedation
in the emergency department (ED)) that may be contributing to poor outcomes.
►► The study challenges the historical paradigm of
deep sedation in the ED by targeting light sedation
in the immediate postintubation phase of care.
►► The pragmatic design will assure all consecutive
patients meeting eligibility criteria will be enroled,
enhancing external validity.
►► Uptake of the protocol may prove more difficult than
anticipated, hindering the ability to target sedation
in the ED.
publication of peer-reviewed manuscripts and the
presentation of abstracts at scientific meetings will be
used to disseminate the work.
Registration C
 linicalTrials.gov identifier NCT04410783;
Pre-results.

INTRODUCTION
Background and rationale
Acute respiratory failure requiring mechanical ventilation in the emergency department (ED) is required for more than 250 000
patients annually in the USA; over 30% of
these patients will die.1–6 This rate can exceed
50% if acute respiratory distress syndrome
develops after admission.3 Even if patients
survive, they experience staggering morbidity
in terms of hospitalisation days, high readmission rates, cognitive decline, psychological
dysfunction and lengthy rehabilitation.7–12
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Scale (RASS) of −3 to −5) in the ED was 53%, and deep
sedation in the ED predicted the receipt of deep sedation
during the first 48 hours in the ICU. ED deep sedation was
also associated with 1.9 fewer ventilator-free days (−0.40
to 4.13), 2.3 fewer hospital-free days (0.26–4.32) and a
13.1% higher incidence of acute brain dysfunction (delirium+coma, odds ratio (95% CI) 1.73 (1.10–2.73)). Despite
this, no ED-based sedation trial has been conducted, and
emergency medicine-
based policy statements mention
nothing regarding light sedation as a potential therapeutic
target.40 These facts suggest that sedation has historically
been viewed as an ‘ICU issue’ and given low priority in the
setting of early critical illness. However, inadequate sedation is not without consequence, as it may increase physiologic stress, catecholamine release, oxygen consumption
and recall of stressful memories.41–44 Therefore, whether
deep sedation in the immediate postintubation period in
the ED is associated with worse outcome remains unclear.
Given the abundance of data showing a strong association between early deep sedation and clinical outcomes,
the lack of clinical trials targeting sedation in the ED, and
the increase use of the ED (in terms of patient visits and
boarding hours) for critically ill patients, there is significant rationale to conduct an ED-based sedation trial in
order to improve outcome.45 Furthermore, given the
influence of ED sedation depth on early ICU sedation,
targeted sedation in the ED could carry benefit, even
for healthcare systems with relatively short ED lengths of
stay. Prior to proceeding with a large-scale clinical trial,
our research team designed the ED-SED Pilot Trial to fill
critical information gaps. The objective of the ED-SED
Pilot Trial is to examine the feasibility of implementing
ED-
based goal-
oriented sedation, which targets light
sedation as the default approach, in patients receiving
mechanical ventilation. We hypothesise that ED-
based
goal-oriented sedation will be feasible in terms of: (1)
trial recruitment; (2) efficacy in achieving target sedation; (3) reliability of RASS measurements during routine
care in the ED; (4) adverse events; and (5) barriers to
implementation.

METHODS AND ANALYSIS
Study design
This is a multicentre (n=3), prospective before-and-after
trial, and is reported in compliance with the Standard
Protocol Items: Recommendations for Intervention Trials
(SPIRIT) statement (see online supplemental file 1). A
schematic of the before-and-after trial design appears in
figure 1. Data collection in the before phase is planned to
begin in August of 2020; data collection in the after phase
is anticipated to be completed in September of 2021.
Study population
This trial will target adult patients receiving mechanical
ventilation in the ED. Inclusion criteria are: (1) mechanical ventilation via an endotracheal tube, including
patients intubated in the ED and prior to arrival (ie,
Fuller BM, et al. BMJ Open 2020;10:e041987. doi:10.1136/bmjopen-2020-041987
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Despite these facts, outcomes for critically ill patients
have improved over the past three decades, largely from
improving the delivery of critical care and optimising
supportive therapies (eg, lung-
protective ventilation,
fluid management, awakening and breathing trials, early
mobility, etc).13–16
Sedation management is a cornerstone therapy for
patients receiving mechanical ventilation, and is highly
influential on outcome. Current sedation guidelines
suggest targeting light levels of sedation depth, unless
clinically indicated otherwise.16 However, the incidence
of deep sedation in the intensive care unit (ICU) is high
(up to 70%), and clinicians frequently extend periods
of deep sedation for days.17 The deep sedation provided
to patients receiving mechanical ventilation is troubling
when considering consequences of deep sedation. Deep
sedation has been associated with an increased incidence
of: (1) ventilator-associated pneumonia18 19; (2) aspiration20; (3) gastrointestinal dysfunction21 22; and (4) deep
venous thrombosis.23 Most relevant to the current work,
these clinical sequela occur early, within 1–2 days, and
provide strong clinical rationale for the avoidance of
deep sedation during the early period of critical illness
when possible.19 23 24 With respect to patient-
oriented
outcomes, deep sedation has a negative impact as shown
by greater: (1) mortality; (2) mechanical ventilation,
ICU and hospital duration; and (3) incidence of post-
traumatic stress disorder, delirium and coma.15 25–31
Early sedation depth may be especially consequential.
Three cohort studies from the ICU found deep sedation
during the initial 48 hours of mechanical ventilation to
be common and associated with increased mechanical
ventilation duration, mortality, incidence of delirium and
longer lengths of stay.32–34 Two pilot trials, not powered
for clinical endpoints, showed a trend of more delirium,
ventilation time and lengths of stay associated with early
deep sedation.35 36 To collate the literature regarding
early sedation and its potential impact on outcome, our
research group conducted a comprehensive systematic
review and meta-analysis, which demonstrated that early
light sedation, compared with deep sedation, was associated with: (1) lower mortality; (2) less delirium; and (3)
fewer ventilator days.37
The ED could be a high-yield clinical arena in which
to target sedation depth to improve outcome. In a single-
centre study, our group demonstrated an incidence
of deep sedation of 64%, and an association between
deep sedation and: (1) increased mortality; (2) fewer
ventilator-
free days; and (3) longer lengths of stay.38
There was a depth-dependent relationship between ED
sedation and outcome such that there were improved
outcomes associated with incrementally lighter ED sedation depth. To build on this single-centre experience,
the multicentre (n=15) ED-SED Study was a prospective
cohort study conducted to examine practice patterns and
clinical outcomes associated with ED sedation across a
diverse sample of medical centres in the USA.39 The incidence of deep sedation (Richmond Agitation-Sedation
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Schematic of the prospective, before-and-after trial design.

prehospital); and (2) age ≥18 years. Exclusion criteria
are: (1) acute neurologic injury (stroke, intracranial
haemorrhage, traumatic brain injury, cardiac arrest,
status epilepticus, fulminant hepatic failure); (2) ongoing
neuromuscular blockade; (3) transfer directly from the
ED to the operating room, or other procedural areas; (4)
death or transition to comfort measures within 24 hours;
(5) transfer to another hospital from the ED; and (6)
chronic/home mechanical ventilation.
Patients will be recruited from the ED at three academic
medical centres in the USA: (1) Barnes-Jewish Hospital/
Washington University School of Medicine, St. Louis,
Missouri; (2) University of Iowa, Iowa City, Iowa; and (3)
Cooper Medical School of Rowan University, Camden,
New Jersey. Patients receiving mechanical ventilation
in the ED reflect the composition of the demographics
at each of the sites in this study. Based on our preliminary data, we project that the enrolment of women will
be approximately 45% and the enrolment of minorities
will be approximately 35% African-American and 10%
Hispanic. We will not exclude any subjects based on
gender, race or ethnicity. We therefore expect that the
study findings will hold external validity.
Screening and study initiation
This study will identify patients presenting to the ED
requiring mechanical ventilation in three academic
centres. Each site has a system in place for real-time alerts
(24 hours/day) when mechanical ventilation is used in
the ED, and has validated its notification system from
the ED to ensure the population of potentially eligible
patients will be consecutive patients receiving mechanical
ventilation presenting to the ED.39 All patients who satisfy
inclusion and exclusion criteria will be enroled.
Patient and public involvement
The patients in this study were not involved in the development of the research question or study design, and will
not be involved in recruitment or conduct of the study.
Interventions
Patients in the before phase of the trial will receive usual
care, which is clinician-directed sedation after the initiation of mechanical ventilation. A pragmatic approach will
be used, and other cointerventions will be at the discretion of the treating clinician and will not be standardised.
After half of the patients have been enroled, the before
phase will end and enrolment will be suspended for
a 3-
month execution of the protocol implementation
Fuller BM, et al. BMJ Open 2020;10:e041987. doi:10.1136/bmjopen-2020-041987

phase. This is an educational initiative aimed at
improving how existing sedation protocols are delivered
to patients receiving mechanical ventilation in the ED.
During this implementation phase, the study team will
engage key stakeholders (ie, nursing leadership, nurses,
attending and resident physicians) regarding our clinical
outcome data on the importance of an ED-based sedation protocol, and the objectives of the research. We
will educate with in-person training (ie, in-services and
lectures) and computer-
based educational strategies
icudelirium.
org) focused on the importance
(eg, www.
of sedation protocols and sedation depth on patient
outcome, aspects of the protocol related to medication
titration, and sedation assessment with RASS. We will also
strategically place marketing tools, such as graphics and
pocket cards, throughout the ED. We will evaluate the
use of sedation throughout the study in order to better
understand providers’ perception of and experience with
ED-based sedation protocols. This will include informal
interactions regarding the progress of adhering to sedation recommendations and ongoing support throughout
the study. We will also conduct a qualitative sedation
knowledge and impediment survey in order to interpret
study results through the lens of qualitative findings, and
to better understand facilitators and barriers to sedation protocol implementation. These surveys will assess
providers’ perception of sedation, and other aspects of
daily practice, which are vital in protocol implementation (ie, support, teamwork, resource availability).46 The
survey will be administered prior to the after phase of the
trial, and following completion of patient enrolment (see
online supplemental file 2).
The implementation phase is needed for two primary
reasons. First, while sedation is standard care for patients
receiving mechanical ventilation, the overwhelming
majority of data comes from the ICU.16 The lack of
emphasis on ED-based sedation is likely driven by: (1)
comparatively sparse data from the ED domain; and (2)
clinical differences, at times vast, between the two locations (ie, nurse-to-patient ratios, acuity, physician staffing).
Therefore, implementation must proceed in a way that
is feasible and balances clinical realities in a way that is
both provider and patient oriented. Implementation will
proceed such that provider feedback is solicited so that
targeted sedation is effectively used in the ED, allowing
us to test the intervention under real-world conditions.
Second, during implementation, sites will not be considered as exposed or not exposed, allowing mitigation of
3
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Figure 1
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Data
Patient-level data will be easily accessible from the electronic medical record. The following baseline characteristics will be collected: age, gender, race, weight, height,

pre-existing comorbid conditions, vital signs at presentation and pertinent laboratory variables. The location of
intubation will be collected (ie, ED, prehospital, outside
hospital/other facility), as will drugs used to facilitate
intubation, and ventilator settings. After the initiation of
mechanical ventilation in the ED, all medications related
to analgesia and sedation in the ED will be collected, and
will include opiates, benzodiazepines, propofol, ketamine,
dexmedetomidine, etomidate, haloperidol, quetiapine
and neuromuscular blockers. Sedation depth in the ED
will be recorded by bedside nurses, using RASS.47
The following in-hospital data will be collected: duration of ventilation, agents used for analgesia and sedation
during the first 48 hours of ICU admission, depth of sedation during the first 7 days of ICU admission, incidence
of acute brain dysfunction, lengths of stay in the ICU and
hospital, discharge location and mortality status. Table 1
shows a description of events for this study.
A data and safety monitoring board (DSMB), independent of the research team and funder, will be used
to monitor the data. The DSMB will assess safety and
efficacy of study procedures, and monitoring the overall
conduct of the study. The DSMB also will review adverse
event data, other safety data, quality and completeness
of study data, protocol adherence data and enrolment
data at each meeting to ensure proper trial conduct and

Table 1 Schedule of events for this prospective, before-and-after trial
Measurement/event

0*

1

2

3

4

5

6

7

Hosp D/C

Inclusion/exclusion criteria
Demographics

X
X

               
               

Comorbid conditions

X

               

Height, weight, PBW, BMI

X

               

Vital signs and pertinent labs

X

               

Illness severity—SOFA

X

               

Intubation details

X

               

Ventilator settings and data

X

               

ED process of care variables

X

               

Adverse events†

X

               

Medications for sedation

X

X

X

           

RASS measurements

X

X

X

X

X

X

X

X

 

X

X

X

X

 

Incidence of deep sedation

X

X

X

X

Blood gas assessment

X

X

X

           

X

X

X

Delirium assessment, CAM-ICU

X

Ventilator status

                X

X

X

X

X

 

Length of stay (hospital and healthcare facility)

                X

Discharge location
Mortality status

                X
                X

*Day 0 refers to the ED.
†Inadvertent extubation, device removal, awareness with paralysis.
BMI, body mass index; CAM, confusion assessment method; ED, emergency department; ICU, intensive care unit; PBW, predicted body
weight; RASS, richmond agitation-sedation scale; SOFA, sequential organ failure assessment.
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contamination risk. To maintain a pragmatic approach to
the study, and because the sedation recommendations are
quite similar across sites, this study will not alter anything
about the post-intubation care at a site (ie, medications
delivered). It will only educate providers on the importance of using a sedation protocol effectively, including:
(1) addressing pain first; (2) setting a target sedation
depth; (3) targeting a light sedation depth (RASS −2 to
0) as the default approach; and (4) appropriately titrated
sedation.
After the 3-
month implementation phase, we will
resume enrolment, and these subjects will comprise the
after phase of the study. Participants in the after phase
will also receive standard postintubation care at the
discretion of the treating team, though it will be after
the education initiative aimed at improving sedation
practices in the ED. While light sedation (RASS 0 to −2)
will be emphasised during the education initiative as the
most appropriate approach for the majority of patients,
patients will be treated and sedated at the discretion of
the clinical team. During the after phase, routine monitoring of sedation practices will occur.

Open access

Outcomes
Several overarching themes exist as reasons to conduct
pilot studies, including those related to process,
resources, management and intervention effects.48 The
main purpose of this pilot study relates to process. Therefore, the outcome measures revolve around feasibility,
not clinical outcomes, and this pilot and its outcome
measures have been designed to specifically address the
unanswered questions that remain despite our preliminary data. Quantitative feasibility outcomes include: (1)
participant recruitment; (2) proportion of RASS scores
in the deep sedation range; (3) reliability (agreement)
of RASS measurements performed by bedside ED nurses
and study team members; and (4) adverse events. These
data will be supplemented with a qualitative assessment of
barriers to implementation (survey of nurses and physicians). While the main purpose of the study is to test
feasibility, we will also collect clinical outcome data and
adverse events potentially related to ED-based sedation
(inadvertent extubation, device removal and awareness
with paralysis).
Proposed statistical methods
This pilot study was designed to test our procedures and
estimate the proportions of our participants who would
meet our feasibility objectives in a powered clinical trial.
Therefore, the data analyses are mostly descriptive.
Demographic and treatment variables, as well as participant characteristics, will be summarised by using descriptive statistics such as mean (SD) and median (IQR) for
continuous variables, and frequency distributions for
categorical variables.
For recruitment rate and adverse events, the type of
data will include Poisson count and binary. Point estimates and confidence intervals will be presented for
data analyses. Based on empirical data, the methods for
confidence intervals may be based on the normal distribution approximation to Poisson/binomial distribution
(when Poisson mean >10 or the number of binomial
events >10), or the exact method (when Poisson mean or
number of binomial events is small). The proportion of
deep sedation measurements before and after the intervention will be compared using the χ2 test to compare two
independent proportions. Logistic regression will be used
to compare before-
and-
after differences, adjusting for
potential confounders. The inter-rater correlation coefficient will be used to assess paired observations between
a study team member and bedside ED nurses, and to
describe reliability of RASS measurements (continuous
Fuller BM, et al. BMJ Open 2020;10:e041987. doi:10.1136/bmjopen-2020-041987

way random effects, in which two raters
scale). Two-
in each site (ie, study team member and bedside ED
nurse) are considered as a random sample from a larger
population, will be used.49 Point estimates of inter-rater
correlation coefficient and 95% CIs will be presented.
Regarding the survey results describing potential barriers
to the implementation, these data will be summarised and
reported as frequencies and proportions, and responses
from time 1 (before protocol) will be compared with time
2 (after completion of the pilot study). Using inductive
content analysis, free text from open-ended questions will
be systematically reviewed line by line to identify themes
around sedation protocol use.50 All tests will be two-
tailed, and a p value <0.05 will be considered statistically
significant.
Sample size
The sample size is based on the proportion of RASS scores
in the deep sedation range, as that is most applicable in
assessing protocol success. Our preliminary data from
the three sites in the ED-SED Pilot Trial demonstrate
that 63% of RASS assessments are expected to be in the
deep sedation range. We assume an effect size (absolute
proportion difference) of 15% (ie, deep sedation 63%
in the before phase and 48% in the after phase), which
is: (1) within the expected range based on an ICU sedation trial which targeted light sedation35; (2) feasible to
attain; and (3) a clinically meaningful demonstration of
adherence to light sedation per the protocol. Assuming
α=0.05 and power=0.80 (two-tailed), 172 patients will be
needed in each phase, that is, a total of 344 patients.
For the reliability aim of the study, a convenience
sample of 25 patients at each site will be used. The RASS
takes less than 20 s to perform, requires minimal training
and has been shown to be highly reliable among multiple
types of healthcare professionals.51 52 Paired observations
of two raters will be conducted on each patient: a study
team member and the bedside ED nurse. The sample
size determination is based on the precision of inter-rater
correlation coefficient estimates. With a desired sample
inter-rater correlation coefficient of 0.95, 23 patients in
each site are needed to produce a one-sided 95% CI with
a lower bound of 0.90, which indicates ‘excellent’ reliability. With a sample of 25 patients at each site, there will
be high precision in the estimation of agreement in RASS
measurements between study team members and bedside
ED nurses in the after phase of the trial.
Anticipated results
The goal enrolment is 0.3 patients per day at each site.
This is realistic given the nature of the trial design for
this pilot and the future trial, and based on the previous
experience of members of the research team in studying
patients receiving mechanical ventilation in ED.2–5 39 53
With successful implementation of targeted sedation in
the ED, we expect to: (1) achieve a 15% reduction in the
proportion of RASS scores in the deep sedation range;
and (2) demonstrate high agreement among RASS
5
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continued feasibility of answering the research questions.
Meetings between the research team and the DSMB will
occur before the study begins, on completion of the
before phase of enrolment, after half of the patients in
the after phase have been enroled, and on study completion. As this is a pilot trial primarily aimed at assessing
feasibility, there will be no stopping guidelines for the
study.

Open access

Data storage and management
All data will be entered by the study team and data accuracy will be verified by the study principal investigator
(PI). Data quality control measures will include queries
to identify missing data, outliers and discrepancies. Only
study team members will have access to protected health
information. After enrolment, a unique identifier will be
assigned to each study subject. The data will be uploaded
and stored using Research Electronic Data Capture
(REDCap), a web-based data management application.
All computers will be password-protected and encrypted
per university policy. We will ensure that the anonymity is
maintained. Patients will not be identified by name in any
reports on this study. The study PI will have access to the
final study dataset.
Ethics and dissemination
Ethics approval
Washington University in St. Louis will act as the single
institutional review board for this trial. The study protocol
has received ethical approval by the Human Research
Protection Office at Washington University School of
Medicine in St. Louis, and will be conducted with waiver
of informed consent.
Dissemination and data sharing
Sharing of data generated by this trial is an important
part of the proposed activities. Data will be shared with
other investigators through academically established
means, as necessary and appropriate. Datasets generated
from the trial will be available from the overall study PI
on reasonable request. Collaboration with others investigators is encouraged. The results will be disseminated via
publication in a peer-reviewed journal and presentation
at national meetings.
Strengths and limitations
Strengths
The genesis of early sedation is in the ED, and our
preliminary data suggest that optimisation of ED-based
sedation could improve both early ICU sedation and
patient-oriented clinical outcomes. Therefore, we believe
the most high impact approach is to focus and initiate
future investigations in the ED domain. Given the
6

lack of ED-based clinical sedation trials that have been
conducted, the ED-SED Pilot Trial was designed to assess
feasibility of implementing targeted sedation in the ED in
preparation for a large-scale clinical trial.
The study has several strengths. It aims to identify
a new potential therapeutic target (ie, targeted sedation) in immediate postintubation care. Deep sedation
has been the default, especially during the early period
of mechanical ventilation, as shown by a number of
studies.32 33 59 Rather than studying a completely new
therapy, the proposed study will generate new knowledge
about a standard component of supportive care that may
already be contributing to poor outcomes. Furthermore,
we propose a proactive approach to targeted sedation
during the most acute phase of respiratory failure. The
historical paradigm has focused on reactive interventions
to reverse unresponsiveness, as most sedation trials have
waited 48–96 hours before randomisation and study initiation.15 25 30 60–62
Our study also differs from a recent early ICU sedation
trial in several ways.63 First, the ED-SED Pilot will account
for both ED and ICU sedation, as opposed to ICU sedation only. Second, sedation depth will be the target, as
opposed to a particular drug (eg, dexmedetomidine), as
it is possible that targeting light sedation in the ED, where
it has not been the norm, will be more impactful and
achieve greater separation in the first days of ICU care.
Third, the pragmatic design will assure that all consecutive patients meeting eligibility criteria will be enroled,
which will generate data that are more externally valid.
Limitations
This study also has several limitations. Protocol uptake
may be suboptimal and implementation may be more
difficult than anticipated. A documented decrease in the
proportion of RASS measurements in the deep sedation
range will be vital to demonstrate feasibility. We believe
this is possible for several reasons. We will assess provider
perceptions regarding the protocol with a qualitative
survey that is administered before and after enrolment.
This will allow modifications of the ED-
SED Protocol
if themes regarding non-
adherence to the protocol
are identified. Targeted sedation protocols have been
successfully implemented in the ICU setting for years.
While the ED environment is unique, there is no empiric
reason to believe that sedation protocols would be inherently difficult to implement in the ED. The agreement in
RASS assessments between trained study team members
and bedside ED nurses may be low. This lack of fidelity
would hinder our ability to conduct a large-scale clinical
trial across multiple sites. While RASS has not been examined in the ED in a similar context as this pilot, there is
extensive ICU data demonstrating excellent inter-rater
reliability among multiple types of healthcare providers.
Given the fact that this aspect of the ED-SED Pilot is also
quite simple (RASS takes <20 s to perform) and reliable,
we anticipate similar success. From a methodology standand-
after studies are prone to temporal
point, before-
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assessments between trained study team members and
bedside ED nurses. Guidelines recommend sedation
protocols and light sedation in patients receiving mechanical ventilation because of a favourable risk-
to-
benefit
ratio, with consistent data showing improved outcomes.16
However, as a trial such as this has not previously been
conducted in the ED, tracking adverse events will be vital
for patient safety and clinical trial planning. We expect
the incidence of adverse events to be similar between
the before and after groups, with the following baseline
expected event rates: self-extubation (<1%),54 55 device
removal (eg, urinary catheter, venous or arterial access,
enteric tubes (1%–2%))56 and awareness with paralysis
(~1%).57 58
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changes and imbalance between study groups. The
relatively short duration of enrolment and pre-existing
standardisation of cointerventions suggests this will not
occur, but any imbalances will be reported. The enrolment window for the before and after periods may lead
to seasonal imbalances regarding indications leading to
respiratory failure in the ED. However, our prior work
has not revealed this to be very significant.2 The study
design limits any associations between any interventions
and outcomes, and will also not be powered for clinical
outcomes. This is not the primary intent of this investigation, but rather to assess feasibility in order to better plan
for a larger trial. In that regard, the ED-SED Pilot could
be a pivotal trial in the process of optimising ED-based
postintubation care in order to reduce adverse events and
improve clinical outcome.
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whether they will have ultimate authority over any of these activities
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adjudication committee, data management team, and other individuals or groups overseeing the trial, if
applicable (see Item 21a for data monitoring committee)
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Introduction
Background and
rationale

6a

Description of research question and justification for undertaking the trial, including summary of relevant
studies (published and unpublished) examining benefits and harms for each intervention

___5,6_________

6b

Explanation for choice of comparators

___6__________

Objectives

7

Specific objectives or hypotheses

___7__________

Trial design

8

Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group),
allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)

___7__________

Methods: Participants, interventions, and outcomes
Study setting

9

Description of study settings (eg, community clinic, academic hospital) and list of countries where data will
be collected. Reference to where list of study sites can be obtained

___7,8_________

Eligibility criteria

10

Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and
individuals who will perform the interventions (eg, surgeons, psychotherapists)

___7,8_________

Interventions

11a

Interventions for each group with sufficient detail to allow replication, including how and when they will be
administered

___9_________

11b

Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose
change in response to harms, participant request, or improving/worsening disease)

__NA_________

11c

Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence
(eg, drug tablet return, laboratory tests)

__9, 10______

11d

Relevant concomitant care and interventions that are permitted or prohibited during the trial

____9_________

Outcomes

12

Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood
pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, ___13_________
median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen
efficacy and harm outcomes is strongly recommended

Participant timeline

13

Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for Figure 1, Table 1
participants. A schematic diagram is highly recommended (see Figure)
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Sample size

14

Estimated number of participants needed to achieve study objectives and how it was determined, including
clinical and statistical assumptions supporting any sample size calculations

___14, 15_____

Recruitment

15

Strategies for achieving adequate participant enrolment to reach target sample size

___8________

Methods: Assignment of interventions (for controlled trials)
Allocation:
Sequence
generation

16a

Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any
___NA_______
factors for stratification. To reduce predictability of a random sequence, details of any planned restriction
(eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants
or assign interventions

Allocation
concealment
mechanism

16b

Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered,
opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned

____NA______

Implementation

16c

Who will generate the allocation sequence, who will enrol participants, and who will assign participants to
interventions

___NA_______

Blinding (masking)

17a

Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome
assessors, data analysts), and how

____NA______

17b

If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant’s
allocated intervention during the trial

____NA______

Methods: Data collection, management, and analysis
Data collection
methods

18a

Plans for assessment and collection of outcome, baseline, and other trial data, including any related
___11______
processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of
study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.
Reference to where data collection forms can be found, if not in the protocol

18b

Plans to promote participant retention and complete follow-up, including list of any outcome data to be
collected for participants who discontinue or deviate from intervention protocols

___NA_______
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Data management

19

Plans for data entry, coding, security, and storage, including any related processes to promote data quality
(eg, double data entry; range checks for data values). Reference to where details of data management
procedures can be found, if not in the protocol

___16________

Statistical methods

20a

Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the
statistical analysis plan can be found, if not in the protocol

__13, 14______

20b

Methods for any additional analyses (eg, subgroup and adjusted analyses)

___NA_________

20c

Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any
statistical methods to handle missing data (eg, multiple imputation)

___NA________

Methods: Monitoring
Data monitoring

21a

Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of __11_________
whether it is independent from the sponsor and competing interests; and reference to where further details
about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not
needed

21b

Description of any interim analyses and stopping guidelines, including who will have access to these interim ___11________
results and make the final decision to terminate the trial

Harms

22

Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse
events and other unintended effects of trial interventions or trial conduct

___11________

Auditing

23

Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent
from investigators and the sponsor

____NA_______

Ethics and dissemination
Research ethics
approval

24

Plans for seeking research ethics committee/institutional review board (REC/IRB) approval

___16, Cover letter

Protocol
amendments

25

Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes,
analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals,
regulators)

___NA________
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26a

Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and
how (see Item 32)

26b

Additional consent provisions for collection and use of participant data and biological specimens in ancillary _NA__________
studies, if applicable

Confidentiality

27

How personal information about potential and enrolled participants will be collected, shared, and maintained ____16_________
in order to protect confidentiality before, during, and after the trial

Declaration of
interests

28

Financial and other competing interests for principal investigators for the overall trial and each study site

___19__________

Access to data

29

Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that
limit such access for investigators

__16___________

Ancillary and posttrial care

30

Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial
participation

____NA______

Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals,
the public, and other relevant groups (eg, via publication, reporting in results databases, or other data
sharing arrangements), including any publication restrictions

____16________

31b

Authorship eligibility guidelines and any intended use of professional writers

__Cover letter___

31c

Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code

___NA________

Informed consent
materials

32

Model consent form and other related documentation given to participants and authorised surrogates

__NA_________

Biological
specimens

33

Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular
analysis in the current trial and for future use in ancillary studies, if applicable

___NA________

Dissemination policy 31a

____NA_______

Appendices

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.
Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
“Attribution-NonCommercial-NoDerivs 3.0 Unported” license.
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Supplementary File 2.

Emergency Department Sedation Protocol Survey
Based on our prior research regarding Emergency Department sedation, we believe
that by improving the process of sedation for mechanically ventilated patients, we can
improve outcome. For research purposes, you are being asked to fill out this survey in
order for us to assess the potential barriers and facilitators to the routine adoption of a
goal-oriented sedation protocol in the ED.
Your Privacy is Protected. The research team will not record any information that
would let someone identify you. The research team will not have access to any of your
personal information. Your responses to this survey are also completely confidential and
will not be shared with anybody.
Your Participation is Voluntary. You may choose to answer this survey or not. If you
choose not to, this will not affect you in any way.
For each item below, please indicate how strongly you agree or disagree with the statement.
● Disagree strongly
● Disagree somewhat
● Agree somewhat
● Agree strongly

1. I believe sedation for mechanically ventilated patients is a common situation frequently
experienced by patients in my ED.
2. I believe sedation for mechanically ventilated patients is managed well in my ED.
3. I believe a sedation protocol is being consistently used in my ED.
4. I believe goal-oriented sedation depth, targeting a specific RASS, is important for patient
outcome.
5. I am confident in my ability to use the RASS to assess depth of sedation.
6. I understand the components of the RASS.
7. I believe assessing depth of sedation with the RASS is too time consuming.
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8. I believe the documentation involved in the RASS is too time consuming.
9. I believe that depth of sedation has an impact on patient outcomes in my ED.
10. I believe the physician’s role is the most important when achieving on-target sedation
depth.
11. I believe the nurse’s role is the most important when achieving on-target sedation depth.
12. I prefer patients to be deeply sedated (unresponsive).
13. I prefer patients to be lightly sedated (calm and interactive).
14. I have the support I need from other personnel to use a sedation protocol in mechanically
ventilated patients.
15. In my ED, it is difficult to speak up if I perceive a problem with patient care.
16. Management/leadership supports my efforts to manage critically ill patients in my ED.
17. Disagreements in my ED are resolved appropriately.
18. It is easy for personnel in my ED to ask questions when there is something that they do not
understand.
19. The physicians and nurses in my ED work together as a well-coordinated team.
20. The levels of staffing in my ED are sufficient to handle the management of mechanically
ventilated patients.
21. I experience good collaboration with nurses in my ED.
22. I experience good collaboration with physicians in my ED.
23. Communication breakdowns that lead to delays in delivery of care are common in my ED.
24. I regularly provide input during the ED stay for mechanically ventilated patients.
25. My input is well received in my ED.
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For each item below, please indicate your answer and/or provide free text answers to
better address the item.
1. The part of the sedation protocol that is most beneficial to patients is: 1) addressing pain in
all patients; 2) having a coordinated care plan with respect to sedation; 3) having a goaloriented RASS target for sedation depth; 4) targeting light sedation; 5) other, please specify
__________
2. The part of the sedation protocol that is least beneficial to patients is: 1) addressing pain in
all patients; 2) having a coordinated care plan with respect to sedation; 3) having a goaloriented RASS target for sedation depth; 4) targeting light sedation; 5) other, please specify
__________
3.

My biggest challenge in implementing a sedation protocol is __________

4.

My biggest concern or fear in implementing a sedation protocol is __________

5.

The best way to improve the sedation protocol in our ED would be __________

6. I learned the most about the sedation protocol by: 1) completing the on-line educational
program; 2) attending in-services; 3) graphics displayed
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